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ttp://dx.doi.org/10.1016/j.jmoldx.2013.11.008Lung cancer is the leading cause of cancer-related deaths worldwide. Prognosis and survival are
dependent on cell type, early detection, and surgical treatment. Hence, optimal screening strategies
and new therapies are urgently required. Although surveillance with low-dose computed tomography
can reduce lung cancer mortality by 20%, the number of false-positive detections is signiﬁcant. Tissue
diagnosis aids in the identiﬁcation of benign nodules, reducing the number of false positive detections.
To determine whether molecular testing of ﬁne-needle aspirations (FNAs) can reduce false-positive
detections, we developed a gene expressionebased test that distinguishes normal from cancerous lung
tissues. The test ﬁrst was applied to published microarray data, showing overall sensitivity and spec-
iﬁcity values of 95% (95% CI, 90%e98%) and 100% (95% CI, 40%e100%), respectively. Subsequently,
it was validated on 30 solid and ex vivo FNA lung cancer tumor samples and matched normal lung
specimens using real-time PCR. The validation test was 93% (95% CI, 78%e99%) sensitive and 100%
(95% CI, 88%e100%) speciﬁc for the detection of tumor versus normal lung on solid samples, whereas
FNA specimens yielded a sensitivity of 91% (95% CI, 72%e99%) and a speciﬁcity of 94% (95% CI,
70%e100%). This study supports the hypothesis that the gene-ratio approach reliably distinguishes
normal lung from cancerous tissues in FNA samples and can be optimized to diagnose benign
nodules. (J Mol Diagn 2014, 16: 267e272; http://dx.doi.org/10.1016/j.jmoldx.2013.11.008)Supported by grants from the National Cancer Institute (R21CA098501
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University, Providence, RI.Lung cancer is the leading cause of cancer-related deaths
worldwide for both men and women.1 Approximately 85%
of lung cancers have histologic features characterized as
non-small cell lung cancer (NSCLC).2 The histologic sub-
types of NSCLC include squamous cell carcinoma, adeno-
carcinoma, adenosquamous carcinoma, and large cell
carcinoma.3 Management of NSCLC usually is determined
by stage of disease at diagnosis. Early stage cancers (I to
IIIA) are treated surgically (with or without neoadjuvant or
adjuvant therapy), and more advanced stage cancers (IIIB to
IV) are treated with chemotherapy with or without radiation
therapy.4,5 The high mortality rate of lung cancer is attrib-
uted to the following: a diagnosis occurring in advanced
stages as a result of the late onset of symptoms, the relative
lack of screening strategies, and ineffective treatment ap-
proaches for advanced cancer. Currently, a deﬁnitive diag-
nosis of cancer in patients with documented pulmonarystigative Pathology
.nodules can be established by surgical resection, percuta-
neous image-guided needle biopsy, or bronchoscopy with
bronchioalveolar lavage.6e8
Percutaneous image-guided, ﬁne-needle aspiration (FNA)
biopsy is a minimally invasive technique that allows
Rienzo et alsampling of tumors for diagnosis. Cells are aspirated directly
from the solid lesion and analyzed by a cytopathologist.9 The
accuracy of this approach, however, diminishes with the size
of the suspected nodule(s) as a consequence of technical
challenges associated with accessing small lesions and the
difﬁculty of obtaining sufﬁcient amounts of cytologically
diagnostic material.10 Until recently, lung cancer subtyping
in FNA specimens was based entirely on morphology.11 The
difﬁcult interpretation of poorly differentiated tumors and the
presence of inadequately preserved samples strongly affected
the cytopathologist’s ability to render an accurate diag-
nosis.11 In addition, the relative lack of tissue architecture
and cellular dispersion in cytology samples further limited
correct tumor subtyping. In more recent years, these barriers
to accurate diagnosis have been removed by increasing
reliance on improved immunocytochemistry and novel
adjunctive molecular biology techniques for more precise
tumor diagnosis.12,13
We previously developed a bioinformatic algorithm using
gene expression ratioebased tests to translate comprehen-
sive expression proﬁling data into simple clinical tests based
on the expression levels of a relatively small number of
genes.14e17 In addition, we have used this algorithm to
generate a gene ratioebased test for the differential diag-
nosis of solitary lung nodules using 23 genes, and we have
tested it in 29 ex vivo FNA biopsies from normal lung and
suspected tumor nodules.18 This algorithm was 87% and
100% accurate in detecting cancer in FNAs from normal
tissue and tumor, respectively.
In this study, we used published microarray data19 to
develop an expression-based test capable of distinguishing
normal lung from lung cancer as a pilot study to determine
the feasibility of using molecular gene-based ratio tests for
the diagnosis of lung cancer. We compared the diagnostic
accuracy of applying the test to FNA biopsy specimens and
to corresponding solid tumor samples from the resected
specimens. Our aim was to determine whether a molecular
test that was capable of distinguishing between normal lung
and cancerous tissues using FNA biopsy could be added toTable 1 Samples Included in the Study
Total number
of analyzed cases Histology
Numb
analy
tumo
16 ADCA 16
14 SQCA 14
2 Carcinoid 2
1 Metastatic breast cancer 1
1 Metastatic colon cancer 1
1 Metastatic renal cell carcinoma 1
1 Metastatic stomach carcinoma 1
1 Metastatic transitional cell carcinoma 1
1 NSC, mixed histology 1
1 NSC, poorly differentiated 1
40 Total 40
ADCA, adenocarcinoma; NSC, non-small cell; SQCA, squamous cell carcinoma.
268cytologic tests to improve the detection and diagnosis of
lung cancer.
Materials and Methods
Tumor and FNA Samples
Studies using human tissues were approved by and con-
ducted in accordance with the policies of the institutional
review board at Brigham and Women’s Hospital and the
Dana Farber Cancer Institute (Boston, MA). Solid tumors
and ex vivo FNAs were collected prospectively from 282
consecutive lung cancer resection specimens at the Brigham
and Women’s Hospital using standard cytopathology tech-
niques as previously described.20 Brieﬂy, immediately after
the tumors were removed, the specimens were transferred to
the frozen section room where FNAs were obtained by a
technician who had been trained by a cytopathologist to
reproduce the in vivo technique using a 22-gauge needle.
Solid areas were visualized, palpated, and FNAs were ob-
tained. Chunks of matching tumor and normal lung samples
from the same patients were acquired and fresh frozen for
comparative analysis. A subset of 30 NSCLC samples and 10
tumor samples of different histologies included in the dif-
ferential diagnosis of solitary pulmonary nodules was
selected randomly. In situ adenocarcinomas were not
included in this analysis. The histologic distribution of the
samples and the number of solid samples and FNA biopsies
available for each case are displayed in Table 1. The frozen
tissues were not microdissected to enrich their tumor content
because it previously has been shown that the repeatability of
the gene ratio is not affected by or related to low levels of
tumor content in tissue specimens.14 The frozen samples and
the ex vivo FNA biopsies were placed in RNA extraction
buffer (TRIzol reagent; Life Technologies Corporation,
Grand Island, NY) and RNA was extracted according to the
manufacturer’s instructions. The RNA was quantiﬁed using
an ND-1000 spectrophotometer (NanoDrop, Fisher Thermo,
Wilmington, DE). RNA samples that showed a 260:280 ratioer of
zed solid
r samples
Number of
analyzed solid
normal samples
Number of
analyzed
tumor FNAs
Number of
analyzed
normal FNAs
16 14 15
14 11 14
2 2 2
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
40 35 39
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Table 2 Samples Included in the Published Microarray19
Histology
Number of analyzed
solid tumor samples
ADCA 139
SQCA 21
Carcinoid 20
SCLC 6
Normal lung 17
ADCA, adenocarcinoma; SCLC, small cell lung cancer; SQCA, squamous cell
carcinoma.
Table 3 List of the Primers for RT-PCR
Primer name Sequence
AGERq33F 50-CAGGACCAGGGAACCTACAG-30
AGERq33R 50-CTGCTCATTGGGGTCATCTT-30
GPR56q56F 50-GCGTGACTTCTTGCTGAGTG-30
GPR56q56F 50-CTCAAAAGGGACCTCCAGCT-30
SPP1q34F 50-CAGTTGCAGCCTTCTCAGC-30
SPP1q34R 50-GGCTAAACCCTGACCCATCT-30
DDR1q25F 50-TTGCAGGTGGATCTACAACG-30
DDR1q25R 50-GAGTGGTGCTGAAGGACCTT-30
Gene-Ratio Test for Lung Cancerless than 1.4 were considered inadequate for the purposes of
the study.
Data Analysis and Gene Expression Ratio Test
To generate the gene expression ratio test for normal versus
tumor specimens, we analyzed a published microarray data
set19 to identify genes that were expressed differentially be-
tween tumor and normal samples. The histologic distribution
and the number of samples in this data set are shown in
Table 2.19 The arrays were searched to identify the probes with
a highly signiﬁcant difference in expression (P  0.01) and at
least twofold absolute expression difference between the two-
sample sets. Eleven genes were selected for further analysis
and several gene ratio tests were calculated. The diagnostic
accuracy of each gene expression ratio test was determined as
previously described.15 Finally, the relative expression levels
of four genes (AGER, GPR56, SSP1, and DDR1) were used to
calculate the geometric mean of three individual gene-pair
expression ratios (AGER/GPR56, AGER/SSP1, and AGER/
DDR1). Samples were assigned a diagnosis of normal lung
when the combined score was greater than 1 and a diagnosis of
lung cancer when the combined score was less than 1.
Real-Time Quantitative RT-PCR
One microgram or 100 ng of total RNA was reverse-
transcribed using a TaqMan reverse-transcription reagent
(Life Technologies Corporation). RT-PCR was performed
using a SYBR Green ﬂuorometry-based detection system
(Life Technologies Corporation), as previously described.16
Primer sequences were synthesized by Invitrogen (Life
Technologies Corporation), and used for RT-PCR as pre-
viously published.15,21 The sequences of the primers are
listed in Table 3. The relative expression levels of the four
selected genes were determined by RT-PCR, and the geo-
metric mean of the three individual gene-pair expression
ratios was calculated. All samples were analyzed at least in
duplicate. Equivocal tests (score Z 1.0) were repeated
starting from the reverse-transcriptase reaction. Samples
receiving an equivocal score (1.0) in two different experi-
ments were excluded from the analysis because it was
impossible to classify the sample as either tumor or normal
lung using the ratio test.The Journal of Molecular Diagnostics - jmd.amjpathol.orgData and Statistical Analysis
The ﬁnal diagnosis for a patient using the gene ratio
expression test was determined by majority rule pooling
across all replicates from an analyzed sample of solid tissue
or FNA.14 In cases in which an equal number of samples
with different assignments were found, a ﬁnal diagnosis
could not be determined, the test result was considered
equivocal, and the case was excluded from the analysis of
evaluable samples. The 95% CIs for rates of sensitivity and
speciﬁcity were based on the exact binomial distribution.
Results
From a published microarray data set (Table 219), a training
set of 26 tumors (13 adenocarcinomas and 13 squamous cell
carcinomas) and 13 normal lung samples was selected
arbitrarily to develop a four-gene, three-ratio, lung cancer
diagnostic test (AGER/GPR56, AGER/SSP1C, and AGER/
DDR1B). The test was examined further in the remaining
samples of the published microarray data19 to determine the
accuracy of the proposed ratio combination in a test cohort.
The overall sensitivity was 95% (95% CI, 90%e98%) and
the speciﬁcity was 100% (95% CI, 40%e100%). The ability
of the test to classify SCLC and metastatic tumors then was
investigated in the remaining 26 microarray samples. Five
SCLC and 19 (92%) pulmonary carcinoid tumor samples
were classiﬁed correctly as lung tumor.
For validation by RT-PCR, a test set of 30 matched tumor
and normal snap-frozen samples was assembled by
randomly selecting the samples from our tumor collection.
The overall sensitivity of the test using RNA extracted from
solid samples was 93% (95% CI, 78%e99%) and the
speciﬁcity was 100% (95% CI, 88%e100%). The same test
was applied to RNAs collected from the matched FNA bi-
opsies, showing a sensitivity of 91% (95% CI, 72%e99%)
and a speciﬁcity of 94% (95% CI, 70%e100%).
To determine whether the test also was accurate in
detecting samples included in the differential diagnosis of a
solitary pulmonary nodule, 10 matched normal and tumor
metastatic solid tissues and FNA biopsies from the same
specimens also were analyzed. The test performed in met-
astatic solid tissues by RT-PCR was 60% (95% CI, 26%e
88%) sensitive and 90% (95% CI, 55%e100%) speciﬁc.269
Table 4 Schematic Representation of the Results by Microarray and RT-PCR
Samples Tumor Normal Sensitivity Speciﬁcity
Microarray data set
Analyzed test set 133 4
Correctly classiﬁed 127 4 95% (95% CI, 90%e98%) 100% (95% CI, 40%e100%)
RT-PCR data set
Lung cancer solid tissues
Analyzed samples 30 30
Correctly classiﬁed samples 28 30 93% (95% CI, 78%e99%) 100% (95% CI, 88%e100%)
Lung cancer FNA biopsies
Analyzed samples 23 16
Correctly classiﬁed 21 15 91% (95% CI, 72%e99%) 94% (95% CI, 70%e100%)
Metastatic solid tissues
Analyzed samples 10 10
Correctly classiﬁed samples 6 9 60% (95% CI, 26%e88%) 90% (95% CI, 55%e100%)
Metastatic FNA biopsies
Analyzed samples 10 9
Correctly classiﬁed samples 8 7 80% (95% CI, 44%e97%) 78% (95% CI, 40%e97%)
Rienzo et alWhen the test was performed using the RNA from the FNA
biopsies, the sensitivity was 80% (95% CI, 44%e97%) and
the speciﬁcity was 78% (95% CI, 40%e97%). A compre-
hensive representation of the results is provided in Table 4.Discussion
We have previously shown that the gene-ratio algorithm can
be applied to diagnostic and prognostic tests using samples
collected by FNA biopsy.18,20 This algorithm identiﬁes
genes that are expressed differentially in two clinically
distinct conditions and calculates ratios for gene pairs that
can predict the condition associated with a test sample. We
have reported that combinations of a small number of
carefully chosen and validated gene expression ratios can be
used to develop diagnostic and prognostic tests for many
types of cancer.14,15,17,22e24 The beneﬁt of this approach is
that it can be used as a stand-alone test with minimal
amounts of nucleic acid material. In addition, we previously
have shown that the FNA biopsy technique captures sufﬁ-
cient RNA for RT-PCR analysis in the majority of cases, but
that there is considerable variability in the quality of RNA
extracted per sample, which more likely is linked to the
technical performance of the procedure rather than to the
speciﬁc tumor evaluated.20 In this study, we successfully
extracted a sufﬁcient quality and quantity of RNA from
ex vivo FNA biopsies from both normal lung and tumor to
show the feasibility of their use in molecular diagnostic
testing for lung cancer. Although the study highlighted
some technical limitations of this approach, most FNAs
yielded accurate and sufﬁcient diagnoses.
The gene expression ratioebased test developed for this
study reliably distinguishes normal lung from pulmonary
adenocarcinoma and squamous cell carcinoma. The test is
not only very sensitive and speciﬁc in solid tissues, but also in
FNA-acquired specimens, which showed 91% (95% CI,27072%e99%) sensitivity and 94% (95% CI, 70%e100%)
speciﬁcity. In addition, the same test can be used to distin-
guish other primary pulmonary tumors and metastatic can-
cers in both microarray and RT-PCR data, albeit with lower
accuracy, indicating that additional reﬁnements are required
to improve the speciﬁcity of the test in metastatic tumors.
One of the limitations of gene ratio-based testing of FNA
biopsy material is the variable RNA quality inherent in these
samples. This limitation ultimately may be overcome by
improving the collection method. In addition, some of the
biopsies yielded contradictory results when RT-PCR was
repeated, which most likely was the result of discrepancies
in the sampling area. In such cases, more than one biopsy
may be required to obtain an accurate diagnosis, but this
does not usually entail signiﬁcant risk or discomfort for the
patient. Finally, we believe that these molecular tests should
be performed in combination with cytologic analysis to take
advantage of a combination of orthogonal technologies to
optimize diagnostic accuracy.
To reduce the mortality of lung cancer, the leading cause
of cancer-related deaths worldwide, more effective
screening strategies and therapies are needed. The challenge
is to ﬁnd an effective, economical screening strategy for
early detection because more than 94 million current and
former smokers are at increased risk. The National Lung
Screening Trial was conducted to determine whether
screening with low-dose computed tomography could
reduce mortality from lung cancer.25,26 Although a 20%
decrease in mortality from lung cancer was observed in the
low-dose computed tomography group compared with the
radiography group, the rate of false-positive results was
higher with low-dose computed tomography screening
because of the presence of benign intrapulmonary lymph
nodes or noncalciﬁed granulomas, which was conﬁrmed
noninvasively by the stability of the ﬁndings on follow-up
computed tomography scans. It is estimated that this
screening program, if instituted, will detect approximatelyjmd.amjpathol.org - The Journal of Molecular Diagnostics
Gene-Ratio Test for Lung Cancer1,000,000 nodules annually, the majority of which will be
benign. Therefore, more accurate tests are required to
identify malignant nodules. One possible approach is to use
percutaneous FNA in combination with molecular tech-
niques to characterize newly discovered pulmonary nodules.
We recommend a combination of molecular and cytologic
testing to enhance the diagnostic accuracy of FNAs.
Microarray analysis allows the simultaneous measure-
ment of expression levels of thousands of genes in a single
experiment to determine molecular variations among
different tissues.27 However, there are still many limitations
in its direct clinical application. The gene-ratio test is a
bioinformatic method that overcomes these limitations and
analyzes tissues for differences in gene expression. There-
fore, it is a valid method for discriminating malignant from
benign nodules.28
Some of the genes identiﬁed in this study also have been
validated in other disease processes by other studies,
including our own.18,29 AGER (also known as the receptor for
advanced glycation end products) encodes a member of the
immunoglobulin superfamily of cell surface molecules that
plays an important role in the development and progression
of vascular disease.30 Recently, disruption of AGER levels
has been implicated in the pathogenesis of a variety of pul-
monary disorders including cancer.31,32 GPR56 encodes a
member of the G-proteinecoupled receptor family; initially,
it was reported to suppress tumor growth and metastasis in
xenograft models using human melanoma cell lines.33
Lately, however, its role in other cancer types appears to be
more complex.34 DDR1 is a receptor tyrosine kinase thought
to play a key role in the communication of cells with their
microenvironment. A recent study that aimed to investigate
the prognostic impact of DDR1 expression in NSCLC
showed that DDR1 up-regulation tends to be observed more
frequently in invasive adenocarcinoma compared with
DDR1 expression in adenocarcinoma in situ and that over-
expression of DDR1 in lung cancer cells results in a signif-
icant increase of cell motility and invasiveness (P < 0.001),
and the interaction of DDR1 with collagen facilitates the
invasiveness of NSCLC cells.35 The selection of the diag-
nostic genes for the normal lung versus lung cancer test was
based solely on bioinformatic rules (eg, stated criteria of
selection), not on biology.
The proposed gene ratio diagnostic approach is suitable for
analyzing FNA biopsies from normal lung and lung tumors
and, ultimately, will be ﬁne-tuned to deﬁne benign nodules
and the transitional zone around tumors. The diagnostic test
for normal lung versus adenocarcinoma and squamous cell
carcinoma shows 91% to 93% sensitivity (95% CI, 72%e
99%) and 94% to 100% speciﬁcity (95% CI, 70%e100%) in
solid samples as well as FNA, thereby proving that FNA
specimens are comparable with solid tumors and are appro-
priate for molecular diagnosis. In addition, most diagnostic
tests with high sensitivity rarely are sufﬁciently speciﬁc to be
useful for broad clinical applications, whereas the gene
expression ratio test is able to distinguish normal lung fromThe Journal of Molecular Diagnostics - jmd.amjpathol.orglung cancer and shows both high sensitivity and high speci-
ﬁcity in solid tissues and FNAs. Therefore, this technique
may complement and extend current cytopathologic tech-
niques for the evaluation of indeterminate and suspicious
lung nodules.Acknowledgment
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